Oncothyreon Inc.
CIK:0001412067|SEC Filings
Consolidated Statements of Operations - USD ($) |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
Dec. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
||||
| Operating expenses | ||||||
| Research and development | $ 43,980,000 | $ 27,467,000 | $ 23,468,000 | |||
| General and administrative | 14,109,000 | 17,630,000 | 9,321,000 | |||
| Intangible asset impairment | 19,738,000 | |||||
| Total operating expenses | 58,089,000 | 64,835,000 | 32,789,000 | |||
| Loss from operations | (58,089,000) | (64,835,000) | (32,789,000) | |||
| Other income | ||||||
| Investment and other income, net | 1,155,000 | 222,000 | 80,000 | |||
| Change in fair value of warrant liability | 128,000 | |||||
| Total other income, net | 1,155,000 | 222,000 | 208,000 | |||
| Loss before income taxes | (56,934,000) | (64,613,000) | (32,581,000) | |||
| Income tax benefit | (6,908,000) | |||||
| Net loss | (56,934,000) | (57,705,000) | (32,581,000) | |||
| Net loss attributable to common stockholders | $ (57,916,000) | $ (60,293,000) | $ (32,581,000) | |||
| Net loss per share basic and diluted (in dollars per share) | [1] | $ (1.21) | $ (3.13) | $ (2.02) | ||
| Shares used to compute basic and diluted net loss per share (1) (in shares) | [1] | 47,966,493 | 19,264,121 | 16,102,860 | ||
| Series E Convertible Preferred Stock [Member] | ||||||
| Other income | ||||||
| Deemed dividend related to beneficial conversion feature on convertible preferred stock | $ (982,000) | $ (2,588,000) | ||||
| ||||||